APR 0 1 2004

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known		
Application Number	10/068,956-Conf. #2381	
Filing Date	February 11, 2002	
First Named Inventor	Paul E. Young	
Art Unit	1653 11,45	
Examiner Name	K. C. Carlson Gase	
Attorney Docket Number	PF513P1	

	<u> </u>		U.S. PATE	NT DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2</sup> ( # known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

		FORE	GN PATENT D	OCUMENTS		
Examine Initials*	r Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>8</sup>
V	A	WO-00/05367-A2	02-03-2000	Sagami Chemical Research Center		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinda Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
16	В	WANG et al., "Human Peptidoglycan Recognition Protein-L Is an N-Acetylmuramoyl-L-alanine Amidase," <i>J. Biol. Chem.</i> 278(49):49044-49052 (Dec. 5, 2003).	
		LIU et al., "Peptidoglycan Recognition Proteins," J. Biol. Chem. 276(37):34686-34694 (Sep. 14, 2001).	
	D	HILLIER et al., GenBank Accession No. AA121766, "zn95a11.r1 Stratagene fetal retina 937202 Homo sapiens cDNA clone IMAGE:565916 5' similar to contains L1.b1 L1 repetitive element;, mRNA sequence". (Feb. 2, 1997)	
	Ε	NCI-CGAP, GenBank Accession No. AA829438, "od27d10.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:1369171 3' similar to contains L1.t3 L1 repetitive element;, mRNA sequence". (Mar. 31, 1998).	
	F	DE PAUW et al., "Characterization of human serum N-acetylmuramyl-L-alanine amidase purified by affinity chromatography," <i>Protein Expr. Purif.</i> 6(3):371-378 (Jun. 1995).	
	G	OCHIAI et al., "A Pattern Recognition Protein for Peptidoglycan," J. Biol. Chem. 274(17):11854-11858 (Apr. 23, 1999).	
	Н	KANG et al., A peptidoglycan recognition protein in innate immunity conserved from insects to humans," <i>Proc. Natl. Acad. Sci. USA</i> 95:10078-10082 (Aug. 1998).	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	Huye	Date Considered	5200

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a/b (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/B/PTO 10/068,956-Conf. #2381 Application Number INFORMATION DISCLOSURE February 11, 2002 Filing Date Paul E. Young STATEMENT BY APPLICANT First Named Inventor 1653 Art Unit

(Use as many sheets as necessary) K. C. Carlson Examiner Name PF513P1 Attorney Docket Number 2 2 of Sheet

REHMAN et al., "Cloning and expression of peptidoglycan recognition protein (PGRP) in the brain and spleen of rattus norvegicus," Society for Neuroscience Abstracts, 25(1-2):1445 (1999), abstract no. 580.4.
J International Search Report for International Application No. PCT/US00/22877 dated Feb. 7, 2001.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is In conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered Examiner Signature

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Young et al.

Docket No.: PF513P1

Application No.: 10/068,956

Confirmation No.: 2381

Filed: February 11, 2002

Art Unit: 1653

For:

PGRP-L Polynucleotides, Polypeptides, and

Examiner: K. C. Carlson

Antibodies

## INFORMATION DISCLOSURE STATEMENT (IDS) PURSUANT TO 37 C.F.R. § 1.56

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to references A-J listed on the attached Form PTO/SB/08. Copies of the references are enclosed.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Accordingly, no fee is believed due. However, should the Patent Office determine otherwise, please charge the required fee to our Deposit Account No. 08-3425.

Dated:

Respectfully submitted,

Joseph Schuller

Registration No.: 48,708

HUMAN GENOME SCIENCES, INC.

14200 Shady Grove Road Rockville, Maryland 20850 (240) 314-4400 x2534

MJH/JS/KN/ba